Ustekinumab Biosimilars
Ustekinumab is a fully human IgG1k monoclonal antibody that binds with high affinity and specificity to the p40 subunit of interleukins (IL-) 12 and 23, inhibiting their activity by preventing binding to their receptors. The European extension of the patent (Supplementary Protection Certificate) of...
Saved in:
| Main Authors: | Elena Carmona-Rocha, Lluís Puig |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2024-11-01
|
| Series: | Biologics |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2673-8449/4/4/25 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Biosimilar SB17 versus reference ustekinumab in moderate to severe plaque psoriasis after switching: phase 3 study results up to week 52
by: Steven R. Feldman, et al.
Published: (2024-12-01) -
A case of ustekinumab-induced pustular psoriasis was treated with IL-17A inhibitor
by: LIN Junjie, et al.
Published: (2024-11-01) -
Blood cytokines as potential predictors of therapy effectiveness in patients with moderate to severe psoriasis treated with the IL-12/IL-23 inhibitor ustekinumab
by: Arfenya E. Karamova, et al.
Published: (2025-03-01) -
Efficacy and safety of ustekinumab in the treatment of moderate to severe plaque psoriasis in Singapore
by: Wai Sze Agnes Chan, et al.
Published: (2023-07-01) -
IgA Vasculitis Induced by Ustekinumab During Treatment for Crohn’s Disease: A Case Report
by: Yu Okada, et al.
Published: (2025-08-01)